Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function

12. november 2026 oppdatert av: University of Minnesota

Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function in Humans

This randomized, double-blind, placebo-controlled pilot study will investigate the effects of an Akkermansia muciniphila-based probiotic supplement, Panthea Core, on autonomic and vascular function in postmenopausal women with hypertension.

Up to 60 participants aged 45 to 65 years will be enrolled to obtain approximately 40 evaluable datasets. Participants will be randomly assigned to receive Panthea Core or a matched placebo capsule daily for 12 weeks.

The study will evaluate safety, tolerability, menopausal symptoms, and changes in autonomic and vascular physiology. The primary mechanistic outcome is muscle sympathetic nerve activity (MSNA), measured using microneurography. Secondary physiological outcomes include heart rate variability, baroreflex sensitivity, endothelial function assessed by flow-mediated dilation, and blood pressure.

Additional assessments will include sleep, menopausal symptoms, mood, cognitive function, circulating metabolic markers, and gut microbiome composition. Participants will complete baseline and post-intervention assessments, with additional safety monitoring throughout supplementation and approximately one month after the intervention.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Akkermansia muciniphila is a bacterium normally found in the human gastrointestinal tract that has been associated with metabolic and immune regulation. Previous research suggests that changes in Akkermansia muciniphila abundance may be related to blood pressure regulation, autonomic nervous system function, and vascular health. However, the effects of direct supplementation on human autonomic and endothelial physiology have not been adequately characterized.

This pilot study will evaluate the effects of a 12-week Akkermansia muciniphila-based probiotic supplement, Panthea Core, in postmenopausal women with hypertension. Hypertension is used as a physiological model of autonomic and vascular dysregulation, rather than as a treatment endpoint.

Participants will be randomized to Panthea Core or matched placebo in a double-blind, parallel-group design. The study plans to recruit up to 60 participants to obtain approximately 40 evaluable datasets.

Participants will complete three in-person study visits, including informed consent and two physiological assessment visits. During the baseline and post-intervention assessments, autonomic nervous system activity will be evaluated using microneurography to measure muscle sympathetic nerve activity, electrocardiography to assess heart rate variability, and physiological testing to assess baroreflex sensitivity.

Vascular endothelial function will be assessed using brachial artery flow-mediated dilation. Blood pressure and heart rate will also be measured.

Additional evaluations include laboratory safety measurements, metabolic and hormonal biomarkers, menopausal symptoms, sleep quality, mood, cognition, anthropometric measurements, dietary intake, and stool-based microbiome profiling.

Participants will take their assigned supplement or placebo daily for 12 weeks. Adverse events and gastrointestinal tolerability will be assessed through biweekly questionnaires and participant-initiated reporting. A follow-up contact approximately one month after the final testing visit will assess additional symptoms and adverse events.

The study is intended to generate preliminary mechanistic, safety, and tolerability data to inform the design of subsequent clinical research. As a pilot study, it is not powered to establish definitive treatment efficacy.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • University of Minnesota - Children's Rehabilitation Center
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

45 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Female individuals, assigned female sex at birth, aged 45 to 65 years.
  • Clinician-diagnosed hypertension, either controlled or uncontrolled.
  • Postmenopausal status, defined as at least 12 months without menstruation or prior surgical removal of the ovaries.
  • Willing and able to provide informed consent.

Exclusion Criteria:

  • Nicotine/tobacco, probiotic, or antibiotic use within the previous six months.
  • Body mass index of 40 kg/m² or greater.
  • Use of hormonal contraceptives or systemic exogenous hormones.
  • Diagnosis of diabetes.
  • Respiratory disease other than well-controlled asthma.
  • Severe neurological conditions, including traumatic brain injury or stroke.
  • Existing endocrine abnormalities.
  • History of chemotherapy.
  • Surgery within the preceding six months.
  • Autoimmune disorders.
  • History of organ transplantation.
  • Digestive disorders, including active or unstable gastrointestinal disease, major gastrointestinal surgery, or motility disorders.
  • Immunosuppressive or glucocorticoid therapy.
  • Chronic illnesses that preclude participation at the investigator's discretion.
  • Intermittent fasting with unwillingness or inability to complete a four-week washout period before enrollment.
  • Inability to speak, read, or understand English.
  • Inability to provide informed consent.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Panthea Core Supplementation

Participants randomized to this group will receive one daily oral capsule of Panthea Core containing live Akkermansia muciniphila and additional dietary supplement ingredients for 12 weeks. Participants will undergo baseline and post-intervention assessments of autonomic and vascular function, safety, and related physiological outcomes.

Panthea Core is an oral probiotic formulation containing live Akkermansia muciniphila (approximately 1 × 10^8 active fluorescence units), pyridoxal-5'-phosphate (10 mg), spermidine trihydrochloride (1.2 mg), and 3,3'-diindolylmethane (100 mg). Participants will take the formulation once daily for 12 weeks. Study product will be distributed through the Investigational Drug Services Pharmacy.

Andre navn:
  • Akkermansia muciniphila-Based Probiotic
  • Panthea Core Supplementation
Placebo komparator: Placebo

Participants randomized to this group will receive a matched placebo capsule daily for 12 weeks. Participants will undergo the same baseline and post-intervention assessments as those assigned to Panthea Core.

Participants will receive a matched oral placebo capsule administered once daily for 12 weeks. The placebo will be supplied by Panthea Inc. and dispensed through the Investigational Drug Services Pharmacy.

Andre navn:
  • Placebo
  • Placebo for Panthea Core

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Muscle Sympathetic Nerve Activity (MSNA)
Tidsramme: Baseline to 12 weeks

Muscle sympathetic nerve activity will be measured using microneurography of the fibular nerve. MSNA burst frequency, expressed as bursts per minute, will be assessed at baseline and after 12 weeks of Panthea Core or placebo supplementation. Changes in MSNA will be compared between treatment groups.

Baseline to 12 weeks
Incidence of Adverse Events
Tidsramme: From initiation of supplementation through approximately 4 weeks after the 12-week intervention

Adverse events and serious adverse events will be monitored throughout the intervention through biweekly REDCap questionnaires, participant-initiated reports, and post-intervention follow-up. The incidence and nature of adverse events will be summarized by treatment group to evaluate the safety and tolerability of Panthea Core.

From initiation of supplementation through approximately 4 weeks after the 12-week intervention
Change in Comprehensive Metabolic Panel Laboratory Measures
Tidsramme: Baseline and 12 weeks

Safety will be evaluated through changes in comprehensive metabolic panel laboratory measurements, including renal function, liver function, and electrolyte measurements. Laboratory results will be assessed at baseline and after 12 weeks of supplementation and summarized by treatment group.

Baseline and 12 weeks
Supplement Adherence
Tidsramme: Throughout the 12-week intervention

Adherence to daily Panthea Core or placebo supplementation will be monitored throughout the intervention using participant-reported information collected through biweekly REDCap questionnaires. Adherence will be summarized descriptively, with a protocol target of at least 80%.

Throughout the 12-week intervention
Study Retention
Tidsramme: From enrollment through completion of the 12-week intervention

Study retention will be assessed as the proportion of enrolled participants who complete the planned intervention and post-intervention assessments. The protocol specifies a retention target of at least 75%.

From enrollment through completion of the 12-week intervention

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Flow-Mediated Dilation (FMD)
Tidsramme: Baseline to 12 weeks

Endothelial function will be assessed using brachial artery ultrasound flow-mediated dilation, expressed as percentage change in vessel diameter following temporary forearm occlusion.

Baseline to 12 weeks
Change in Heart Rate Variability (HRV)
Tidsramme: Baseline to 12 weeks

Cardiovagal modulation will be evaluated using time-domain and frequency-domain measures derived from electrocardiogram recordings.

Baseline to 12 weeks
Change in Cardiovagal Baroreflex Sensitivity
Tidsramme: Baseline to 12 weeks

Cardiovagal baroreflex sensitivity will be assessed using changes in ECG R-R intervals relative to changes in systolic blood pressure, expressed in ms/mmHg.

Baseline to 12 weeks
Change in Sympathetic Baroreflex Sensitivity
Tidsramme: Baseline to 12 weeks

Sympathetic baroreflex sensitivity will be evaluated using changes in MSNA relative to diastolic blood pressure, expressed in bursts/100 heartbeats/mmHg as described in the protocol.

Baseline to 12 weeks
Change in Blood Pressure
Tidsramme: Baseline to 12 weeks

Systolic and diastolic blood pressure will be measured at baseline and after the 12-week intervention to assess changes in blood pressure as a physiological parameter.

Baseline to 12 weeks
Change in Menopause-Specific Quality of Life
Tidsramme: Baseline to 12 weeks

Menopausal symptoms and quality of life will be assessed using the Menopause-Specific Quality of Life (MENQOL) questionnaire, including vasomotor, physical, psychosocial, and sexual domains.

Baseline to 12 weeks
Change in Depressive Symptoms (PHQ-9)
Tidsramme: Baseline to 12 weeks

Depressive symptoms will be evaluated using the nine-item Patient Health Questionnaire (PHQ-9).

Baseline to 12 weeks
Change in Insomnia Severity (ISI)
Tidsramme: Baseline to 12 weeks

Insomnia symptoms will be assessed using the seven-item Insomnia Severity Index.

Baseline to 12 weeks
Change in Subjective Sleep Quality (PSQI)
Tidsramme: Baseline to 12 weeks

(PSQI) Subjective sleep quality and disturbances will be assessed using the Pittsburgh Sleep Quality Index.

Baseline to 12 weeks
Change in Objective Sleep Parameters
Tidsramme: Baseline to 12 weeks

Sleep will be measured using WatchPAT ONE-M monitoring before baseline and post-intervention physiological testing.

Baseline to 12 weeks
Change in Cognitive Function (MoCA)
Tidsramme: Baseline to 12 weeks

Cognitive function will be evaluated using Montreal Cognitive Assessment scores before and after supplementation.

Baseline to 12 weeks
Change in Gut Microbiome Composition
Tidsramme: Baseline to 12 weeks

Fecal microbiome sequencing will be used to evaluate changes in microbial composition and the abundance of Akkermansia muciniphila after supplementation.

Baseline to 12 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Manda Keller-Ross, University of Minnesota

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. februar 2027

Primær fullføring (Antatt)

31. januar 2030

Studiet fullført (Antatt)

31. januar 2030

Datoer for studieregistrering

Først innsendt

12. november 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • PT-2026-34798

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .